Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02028052
Other study ID # Pro00036432
Secondary ID
Status Terminated
Phase N/A
First received December 20, 2013
Last updated February 14, 2017
Start date April 2012
Est. completion date November 2014

Study information

Verified date January 2015
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is comparing the attributable procedural time of Endobronchial Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) when sampling mediastinal and hilar lymph nodes with or without Rapid On-Site Evaluation (ROSE). The primary outcome will be the time elapsed from EBUS bronchoscope insertion to bronchoscope withdrawal. Secondary outcomes will include total number of sampled lymph nodes, average number of needle aspirations per lymph node sampled, overall diagnostic yield, and procedural time of the cytopathologist.


Recruitment information / eligibility

Status Terminated
Enrollment 37
Est. completion date November 2014
Est. primary completion date November 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject provides informed consent

2. Subject is >18 years of age

3. Subject is scheduled to undergo flexible bronchoscopy with EBUS-TBNA of suspected enlarged mediastinal or hilar lymph nodes as part of their standard medical care

4. A negative pregnancy test in women of child-bearing potential

5. Subject is mentally capable of following study directions

Exclusion Criteria:

1. Study subject has any disease or condition that interferes with safe completion of initial or follow-up assessments

2. Concurrent participation in another study involving investigational drugs or investigational medical devices

3. Inability to read and understand the necessary study documents

Study Design


Related Conditions & MeSH terms

  • Benign and Malignant Mediastinal and Hilar Lymph Nodes Known or Suspected Malignancy
  • ENDOBRONCHIAL ULTRASOUND - TRANSBRONCHIAL NEEDLE ASPIRATION

Intervention

Procedure:
ROSE
The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
Device:
22 gauge Vizishot needles


Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

References & Publications (4)

Griffin AC, Schwartz LE, Baloch ZW. Utility of on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspiration specimens. Cytojournal. 2011;8:20. doi: 10.4103/1742-6413.90081. — View Citation

Layfield LJ, Bentz JS, Gopez EV. Immediate on-site interpretation of fine-needle aspiration smears: a cost and compensation analysis. Cancer. 2001 Oct 25;93(5):319-22. — View Citation

Mejia CP. [Surgery and orthodontics in the treatment of unerupted maxillary cuspids]. Rev Fed Odontol Colomb. 1976 Jan-Jun;24(116-117):47-52. Spanish. — View Citation

Yasufuku K, Chiyo M, Sekine Y, Chhajed PN, Shibuya K, Iizasa T, Fujisawa T. Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest. 2004 Jul;126(1):122-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time lapse The primary endpoint is the time elapsed from EBUS bronchoscope insertion to bronchoscope withdrawal. during procedure, approximately 45 minutes
Secondary Total number of sampled lymph nodes Samples taken during procedure approximately 45 minutes
Secondary Average number of needle aspirations per lymph node sampled Determined by tumor approximately 45 minutes
Secondary Overall diagnostic yield approximately 45 minutes
Secondary Procedural time of the cytopathologist approximately 30 minutes